Tevogen Inc.TVGN
Price (close)
$7.85
Market cap
$51.1M
P/E
—
Revenue (TTM)
—
Net income
-$21.6M
Dividend yield
—
1-year total return
-80.0%
Net margin
—
Revenue growth
—
Debt / equity
—
What Tevogen Inc. does.
are a clinical-stage specialty immunotherapy company harnessing one of nature’s most powerful immunological weapons, CD8+ cytotoxic
T lymphocytes (“CTLs”), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers,
and other disorders, with the aim of addressing the significant unmet needs of large patient populations. We believe that sustainability
Revenue and profit, by fiscal year.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Net income | — | $4.4M | -$60.5M | -$13.7M | -$26.3M |
| Free cash flow | — | — | -$8.3M | — | -$12.4M |
More on TVGN.
- Tevogen Inc. summary
- Tevogen Inc. financial statements
- Tevogen Inc. key metrics
- Tevogen Inc. health scores and style box
- Tevogen Inc. earnings
- Tevogen Inc. dividends
- Tevogen Inc. valuation
- Tevogen Inc. ownership and insiders
- Tevogen Inc. peers
Figures from Tevogen Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.